Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094642095> ?p ?o ?g. }
- W2094642095 endingPage "5978" @default.
- W2094642095 startingPage "5960" @default.
- W2094642095 abstract "Interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK or TXK) are essential mediators of intracellular signaling in both normal and neoplastic T-cells and natural killer (NK) cells. Thus, ITK and RLK inhibitors have therapeutic potential in a number of human autoimmune, inflammatory, and malignant diseases. Here we describe a novel ITK/RLK inhibitor, PRN694, which covalently binds to cysteine residues 442 of ITK and 350 of RLK and blocks kinase activity. Molecular modeling was utilized to design molecules that interact with cysteine while binding to the ATP binding site in the kinase domain. PRN694 exhibits extended target residence time on ITK and RLK and is highly selective for a subset of the TEC kinase family. In vitro cellular assays confirm that PRN694 prevents T-cell receptor- and Fc receptor-induced cellular and molecular activation, inhibits T-cell receptor-induced T-cell proliferation, and blocks proinflammatory cytokine release as well as activation of Th17 cells. Ex vivo assays demonstrate inhibitory activity against T-cell prolymphocytic leukemia cells, and in vivo assays demonstrate durable pharmacodynamic effects on ITK, which reduces an oxazolone-induced delayed type hypersensitivity reaction. These data indicate that PRN694 is a highly selective and potent covalent inhibitor of ITK and RLK, and its extended target residence time enables durable attenuation of effector cells in vitro and in vivo. The results from this study highlight potential applications of this dual inhibitor for the treatment of T-cell- or NK cell-mediated inflammatory, autoimmune, and malignant diseases. Interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK or TXK) are essential mediators of intracellular signaling in both normal and neoplastic T-cells and natural killer (NK) cells. Thus, ITK and RLK inhibitors have therapeutic potential in a number of human autoimmune, inflammatory, and malignant diseases. Here we describe a novel ITK/RLK inhibitor, PRN694, which covalently binds to cysteine residues 442 of ITK and 350 of RLK and blocks kinase activity. Molecular modeling was utilized to design molecules that interact with cysteine while binding to the ATP binding site in the kinase domain. PRN694 exhibits extended target residence time on ITK and RLK and is highly selective for a subset of the TEC kinase family. In vitro cellular assays confirm that PRN694 prevents T-cell receptor- and Fc receptor-induced cellular and molecular activation, inhibits T-cell receptor-induced T-cell proliferation, and blocks proinflammatory cytokine release as well as activation of Th17 cells. Ex vivo assays demonstrate inhibitory activity against T-cell prolymphocytic leukemia cells, and in vivo assays demonstrate durable pharmacodynamic effects on ITK, which reduces an oxazolone-induced delayed type hypersensitivity reaction. These data indicate that PRN694 is a highly selective and potent covalent inhibitor of ITK and RLK, and its extended target residence time enables durable attenuation of effector cells in vitro and in vivo. The results from this study highlight potential applications of this dual inhibitor for the treatment of T-cell- or NK cell-mediated inflammatory, autoimmune, and malignant diseases." @default.
- W2094642095 created "2016-06-24" @default.
- W2094642095 creator A5021564306 @default.
- W2094642095 creator A5029949716 @default.
- W2094642095 creator A5032842967 @default.
- W2094642095 creator A5033606709 @default.
- W2094642095 creator A5036650726 @default.
- W2094642095 creator A5038989480 @default.
- W2094642095 creator A5041950455 @default.
- W2094642095 creator A5043721826 @default.
- W2094642095 creator A5051145637 @default.
- W2094642095 creator A5056327118 @default.
- W2094642095 creator A5063390263 @default.
- W2094642095 creator A5070756852 @default.
- W2094642095 creator A5071916490 @default.
- W2094642095 creator A5072175892 @default.
- W2094642095 creator A5077081162 @default.
- W2094642095 creator A5078301912 @default.
- W2094642095 creator A5080843317 @default.
- W2094642095 date "2015-03-01" @default.
- W2094642095 modified "2023-09-30" @default.
- W2094642095 title "Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694" @default.
- W2094642095 cites W1480439893 @default.
- W2094642095 cites W1517868493 @default.
- W2094642095 cites W1562437391 @default.
- W2094642095 cites W1951217465 @default.
- W2094642095 cites W1964706407 @default.
- W2094642095 cites W1965064476 @default.
- W2094642095 cites W1976173775 @default.
- W2094642095 cites W1977946844 @default.
- W2094642095 cites W1986156270 @default.
- W2094642095 cites W1986259463 @default.
- W2094642095 cites W1993273784 @default.
- W2094642095 cites W1997734251 @default.
- W2094642095 cites W2000076767 @default.
- W2094642095 cites W2005553679 @default.
- W2094642095 cites W2010826871 @default.
- W2094642095 cites W2015551897 @default.
- W2094642095 cites W2019216438 @default.
- W2094642095 cites W2021848632 @default.
- W2094642095 cites W2021922201 @default.
- W2094642095 cites W2022069273 @default.
- W2094642095 cites W2028842451 @default.
- W2094642095 cites W2029336928 @default.
- W2094642095 cites W2034946023 @default.
- W2094642095 cites W2040140683 @default.
- W2094642095 cites W2041215937 @default.
- W2094642095 cites W2045964805 @default.
- W2094642095 cites W2050818562 @default.
- W2094642095 cites W2052831496 @default.
- W2094642095 cites W2053463045 @default.
- W2094642095 cites W2056018279 @default.
- W2094642095 cites W2059271361 @default.
- W2094642095 cites W2062131034 @default.
- W2094642095 cites W2066556559 @default.
- W2094642095 cites W2067973732 @default.
- W2094642095 cites W2071549499 @default.
- W2094642095 cites W2072338892 @default.
- W2094642095 cites W2078275018 @default.
- W2094642095 cites W2079130077 @default.
- W2094642095 cites W2085314117 @default.
- W2094642095 cites W2089103836 @default.
- W2094642095 cites W2092374642 @default.
- W2094642095 cites W2092972397 @default.
- W2094642095 cites W2095607685 @default.
- W2094642095 cites W2096204062 @default.
- W2094642095 cites W2096843911 @default.
- W2094642095 cites W2097275791 @default.
- W2094642095 cites W2099308699 @default.
- W2094642095 cites W2100941609 @default.
- W2094642095 cites W2103890955 @default.
- W2094642095 cites W2107773259 @default.
- W2094642095 cites W2108244474 @default.
- W2094642095 cites W2117340681 @default.
- W2094642095 cites W2120937798 @default.
- W2094642095 cites W2127834887 @default.
- W2094642095 cites W2130622321 @default.
- W2094642095 cites W2132529497 @default.
- W2094642095 cites W2135163046 @default.
- W2094642095 cites W2141091064 @default.
- W2094642095 cites W2151861846 @default.
- W2094642095 cites W2153977062 @default.
- W2094642095 cites W2154066874 @default.
- W2094642095 cites W2154807028 @default.
- W2094642095 cites W2166356293 @default.
- W2094642095 cites W2171297632 @default.
- W2094642095 doi "https://doi.org/10.1074/jbc.m114.614891" @default.
- W2094642095 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4358234" @default.
- W2094642095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25593320" @default.
- W2094642095 hasPublicationYear "2015" @default.
- W2094642095 type Work @default.
- W2094642095 sameAs 2094642095 @default.
- W2094642095 citedByCount "35" @default.
- W2094642095 countsByYear W20946420952015 @default.
- W2094642095 countsByYear W20946420952017 @default.
- W2094642095 countsByYear W20946420952018 @default.
- W2094642095 countsByYear W20946420952019 @default.
- W2094642095 countsByYear W20946420952020 @default.